Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer

Journal of Infection and Chemotherapy

Volumn 16, Issue 3, 2010, Pages 200-205

  Yasufuku, Tomihiko ^a   Shigemura, Katsumi ^a,b   Matsumoto, Osamu ^c   Arakawa, Soichi ^a   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Akashi Municipal Hospital   (Japan)

^c Miki City Hospital   (Japan)

Author keywords

Combination chemotherapy; Docetaxel; Hormone refractory prostate cancer; Paclitaxel

Indexed keywords

BICALUTAMIDE; CARBOPLATIN; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; FLUTAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; UFT;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTIGEN DETECTION; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DRY EYE; FATIGUE; HUMAN; INFECTION; LEUKOPENIA; LIVER DYSFUNCTION; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHLEBITIS; PROSTATE CANCER; SENSORY NEUROPATHY; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 77955718345     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-010-0047-7     Document Type: Article

References (13)

1. Takenaka A, Yamada Y, Kurahashi T, Soga H, Miyake H, Fujisawa M. Combination chemotherapy with weekly docetaxel and estramustine for hormone refractory prostate cancer in Japanese patients. Int J Urol. 2008;15:106-9.
2. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242-5.
3. Urakami S, Yoshino T, Kikuno N, Imai S, Honda S, Yoneda H, et al. Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy resistant hormone-refractory prostate cancer: a pilot study. Urology. 2005;65:543-8.
4. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-20.
5. de Wit R. Chemotherapy in hormone-refractory prostate cancer. BJU Int. 2008;101(Suppl 2):11-5.
6. Engels FK, Verweij J. Docetaxel administration schedule: from fever to tears? A review of randomised studies. Eur J Cancer. 2005;41:1117-26.
7. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-12.
8. Horwitz EM, Vicini FA, Ziaja EL, Dmuchowski CF, Stromberg JS, Martinez AA. The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American Society of Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys. 1998;41:267-72.
9. Caffo O, Sava T, Comploj E, Fariello A, Zustovich F, Segati R, et al. Docetaxel, with or without estramustine phosphate, as firstline chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial. BJU Int. 2008;102:1080-5.
10. Kikuno N, Urakami S, Nakamura S, Hiraoka T, Hyuga T, Arichi N, et al. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer. Eur Urol. 2007;51:1252-8.
11. Arlen PM, Gulley JL. Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer. Future Oncol. 2005;1:19-22.
12. Petrylak DP. New paradigms for advanced prostate cancer. Rev Urol. 2007;9(Suppl 2):3-12.
13. Makarovskiy AN, Siryaporn E, Hixson DC, Akerley W. Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure. Cell Mol Life Sci. 2002;59:1198-211.